Form 4: Corcept Therapeutics Officer Sells Shares

Corcept Therapeutics Chief Development Officer William Guyer exercised stock options and subsequently sold 20,000 shares of common stock.

Summary

• William Guyer, Chief Development Officer of Corcept Therapeutics Inc. (CORT), engaged in transactions involving company stock.
• On October 7, 2025, Guyer exercised options to acquire 20,000 shares of common stock at an exercise price of $21.65 per share.
• Concurrently, Guyer sold 20,000 shares of common stock at a weighted average price of $89.9391 per share, with individual sales ranging from $89.85 to $90.18.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 27, 2024.
• Following these transactions, Guyer beneficially owns 5,287 shares of common stock and 310,000 stock options.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. While an insider sale can be seen negatively, the transaction was pre-planned under a 10b5-1 plan, and the high sale price relative to the exercise price indicates a profitable event for the officer, which is generally a positive for the company's stock performance up to that point.

Positives

• The sale price of $89.9391 per share is significantly higher than the exercise price of $21.65, indicating a substantial profit for the officer on the exercised options.
• The transaction was executed under a pre-arranged 10b5-1 trading plan, which suggests a planned, rather than reactive, sale.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces the officer's direct equity stake.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal, though a 10b5-1 plan mitigates immediate negative implications. The officer still retains a significant number of options.

Key Dates

Recommendation

The filing details a pre-planned insider sale by a Chief Development Officer, which is a routine event for executives managing their equity compensation. While an insider sale reduces direct ownership, the transaction was executed under a 10b5-1 plan, mitigating concerns about opportunistic timing. The significant profit realized by the officer from the option exercise and subsequent sale reflects positively on the company's stock performance leading up to the transaction. However, a Form 4 alone does not provide sufficient information on the company's fundamentals, future prospects, or valuation to warrant a 'buy' or 'sell' recommendation. A 'hold' recommendation is appropriate, pending further analysis of the company's broader financial health and strategic direction.

Keywords

Corcept Therapeutics, CORT, William Guyer, Insider Trading, Form 4, Stock Option Exercise, Stock Sale, 10b5-1 Plan, Chief Development Officer